Intact Investment Management Inc. Biogen Inc. Transaction History

Intact Investment Management Inc.

$2.43 Billion
Q2 2024

A detailed history of Intact Investment Management Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Intact Investment Management Inc. holds 3,530 shares of BIIB stock, worth $690,573. This represents 0.03% of its overall portfolio holdings.

Number of Shares

3,530

Previous 3,000 17.67%

Holding current value

$690,573

Previous $646,000 26.63%

% of portfolio

0.03%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$190.52 - $236.72 $100,975 - $125,461	530 Added 17.67%	3,530 $818,000
Q1 2024 May 03, 2024	BUY	$212.02 - $267.71 $148,414 - $187,397	700 Added 30.43%	3,000 $646,000
Q4 2023 Feb 02, 2024	BUY	$222.59 - $267.94 $511,957 - $616,262	2,300 New	2,300 $595,000
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $82,575 - $95,418	-300 Reduced 15.0%	1,700 $484,000
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $51,312 - $58,467	200 Added 11.11%	2,000 $556,000
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $50,488 - $61,344	-200 Reduced 10.0%	1,800 $498,000
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $389,380 - $536,920	2,000 New	2,000 $534,000
Q2 2019 Jul 30, 2019	SELL	$219.29 - $241.72 $197,361 - $217,548	-900 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$216.71 - $338.96 $65,013 - $101,688	-300 Reduced 25.0%	900 $213,000
Q3 2018 Oct 29, 2018	SELL	$293.51 - $383.83 $58,702 - $76,766	-200 Reduced 14.29%	1,200 $424,000
Q1 2018 May 08, 2018	BUY	$260.13 - $367.91 $52,026 - $73,582	200 Added 16.67%	1,400 $383,000
Q3 2017 Oct 27, 2017	BUY	$281.15 - $329.69 $337,380 - $395,628	1,200	1,200 $376,000

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $28.2B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Intact Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Intact Investment Management Inc. with notifications on news.

Account

Intact Investment Management Inc. Biogen Inc. Transaction History